^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Thymoma |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Excerpt:
The NCCN panel does not recommend pembrolizumab in patients with thymomas because of concerns about immune-related events...
